CGS 26582

Drug Profile

CGS 26582

Latest Information Update: 22 May 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Macrocyclic lactams
  • Mechanism of Action ACE inhibitors; Endopeptidase inhibitors; Endothelin-converting enzyme 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 22 May 2001 No-Development-Reported for Hypertension in USA (Unknown route)
  • 18 Nov 1998 New profile
  • 18 Nov 1998 Preclinical development for Hypertension in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top